```
* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:13:35 ON 09 MAR 2006

=> file bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21


=> set plurals on
SET COMMAND COMPLETED

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        92.16      92.37


     (FILE 'HOME' ENTERED AT 10:13:35 ON 09 MAR 2006)

     FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB,
     CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2,
     DRUGU, EMBAL, EMBASE, ESBIOBASE, FEDRIP, ...' ENTERED AT 10:13:46 ON 09
     MAR 2006
                SET PLURALS ON

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 10:14:02 ON 09 MAR 2006
                SEA CYCLOSPORIN AND CARRIER
               ---------
              11   FILE ADISCTI
               5   FILE ADISNEWS
               2   FILE AGRICOLA
               2   FILE ANABSTR
               5   FILE BIOENG
             143   FILE BIOSIS
              41   FILE BIOTECHABS
              41   FILE BIOTECHDS
             131   FILE BIOTECHNO
               2   FILE CABA
             420   FILE CAPLUS
               1   FILE CEABA-VTB
              38   FILE DDFU
              78   FILE DGENE
               7   FILE DISSABS
              80   FILE DRUGU
               3   FILE EMBAL
             567   FILE EMBASE
              47   FILE ESBIOBASE
               6   FILE GENBANK
             500   FILE IFIPAT
              13   FILE JICST-EPLUS
              32   FILE LIFESCI
             793   FILE MEDLINE
               1   FILE NTIS
             114   FILE PASCAL
               3   FILE PHIN
               9   FILE PROMT
               1   FILE RDISCLOSURE
             175   FILE SCISEARCH
             302   FILE TOXCENTER
            7938   FILE USPATFULL
             760   FILE USPAT2
             273   FILE WPIDS
               1   FILE WPIFV
```

```
             273   FILE WPINDEX
               1   FILE CASREACT
              21   FILE DPCI
               2   FILE ENCOMPPAT
            1336   FILE EPFULL
             109   FILE GBFULL
              40   FILE IMSPATENTS
              99   FILE INPADOC
               5   FILE JAPIO
               5   FILE KOREAPAT
              43   FILE PATDPAFULL
            5497   FILE PCTFULL
               2   FILE RAPRA
               5   FILE RUSSIAPAT
L1              QUE CYCLOSPORIN AND CARRIER
                ---------

     FILE 'USPATFULL, PCTFULL, EPFULL, MEDLINE, USPAT2, EMBASE, IFIPAT,
     CAPLUS, TOXCENTER, WPIDS, SCISEARCH, BIOSIS, BIOTECHNO' ENTERED AT
     10:16:15 ON 09 MAR 2006
L2         18835 S L1
L3        294247 S DIOIC OR PHTHALIC OR ISOPHTHALIC OR TEREPHTHALIC OR AROMATIC
L4         42122 S DIBUTYL SEBACATE OR DIBUTYL PHTHALATE
L5        193352 S NON-IONIC SURFACTANT OR NONIONIC SURFACTANT OR POLYOXYETHYLAT
L6         51340 S GLYCEROL MONOOLEATE OR SORBITAN MONOOLEATE OR GLYCEROL MONOCA
L7        796451 S ANTIOXIDANT OR BHA OR BHT OR ALPHA(1A)TOCOPHEROL

=> s l2 and l3 and l4 and l5 and l6
L8            10 L2 AND L3 AND L4 AND L5 AND L6


=> dup rem l8
PROCESSING COMPLETED FOR L8
L9             8 DUP REM L8 (2 DUPLICATES REMOVED)


=> d bib abs 1-8

L9   ANSWER 1 OF 8  USPATFULL on STN
AN      2006:40290  USPATFULL
TI      Solid   ***carriers***   for improved delivery of active ingredients in
        pharmaceutical compositions
IN      Patel, Mahesh, Salt Lake City, UT, UNITED STATES
PI      US 2006034937      A1   20060216
AI      US 2005-196805     A1   20050802 (11)
RLI     Continuation-in-part of Ser. No. US 2003-428341, filed on 1 May 2003,
        GRANTED, Pat. No. US 6923988 Continuation of Ser. No. US 2001-800593,
        filed on 6 Mar 2001, GRANTED, Pat. No. US 6569463 Division of Ser. No.
        US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT      Utility
FS      APPLICATION
LREP    THORPE NORTH & WESTERN, LLP., 8180 SOUTH 700 EAST, SUITE 200, SANDY, UT,
        84070, US
CLMN    Number of Claims: 18
ECL     Exemplary Claim: 1-81
DRWN    4 Drawing Page(s)
LN.CNT 2964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention provides solid pharmaceutical compositions for
        improved delivery of a wide variety of pharmaceutical active ingredients
        contained therein or separately administered. In one embodiment, the
        solid pharmaceutical composition includes a solid   ***carrier***   , the
        solid   ***carrier***   including a substrate and an encapsulation coat
        on the substrate. The encapsulation coat can include different
        combinations of pharmaceutical active ingredients, hydrophilic
        surfactant, lipophilic surfactants and triglycerides. In another
        embodiment, the solid pharmaceutical composition includes a solid
          ***carrier***   , the solid   ***carrier***   being formed of different
        combinations of pharmaceutical active ingredients, hydrophilic
        surfactants, lipophilic surfactants and triglycerides. The compositions
        of the present invention can be used for improved delivery of
        hydrophilic or hydrophobic pharmaceutical active ingredients, such as
        drugs, nutritional agents, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L9 ANSWER 2 OF 8 USPATFULL on STN DUPLICATE 1
AN 2004:133829 USPATFULL
TI Pharmaceutical compositions
IN Patel, Satishchandra P., Livingston, NJ, UNITED STATES
PI US 2004102366 A1 20040527
AI US 2003-632969 A1 20030804 (10)
PRAI GB 2002-18003 20020802
DT Utility
FS APPLICATION
LREP Edward A. Meilman, DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 41st Floor, 1177 Avenue of the Americas, New York, NY, 10036-2714
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 433
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing:

(a) a pharmaceutically effective amount of a ***cyclosporin*** , in particular ***Cyclosporin*** A,

(b) a ***carrier*** medium which is a dialkyl ester of an aliphatic or ***aromatic*** ***dioic*** ***acid*** , the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or ***aromatic*** ***dioic*** ***acid*** having from 6 to 20 carbon atoms,

(c) a co- ***carrier*** having a hydrophilic lipophilic balance (HLB) of from 3 to 6, and

(d) a ***non*** - ***ionic*** ***surfactant*** having a hydrophilic lipophilic balance (HLB) greater than 10.

Examples of the ***carrier*** medium are ***dibutyl*** ***sebacate*** and ***dibutyl*** ***phthalate*** . Examples of the co- ***carrier*** are ***glycerol*** ***monooleate*** , ***sorbitan*** ***monooleate*** , ***glycerol*** ***monocaprylate*** , and ***sorbitan*** ***monolaurate*** .

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2004012770 PCTFULL ED 20040219 EW 200407
TIEN ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING ***CYCLOSPORIN***
TIFR COMPOSITIONS PHARMACEUTIQUES ORALES CONTENANT DE LA CYCLOSPORINE
IN PATEL, Satishchandra, Punambhai, 27 Yale Court, Livingston, NJ 07039, US [US, US]
PA SMYTH, Gyles, Darren, 57-60 Lincoln's Inn Fields, London WC2A 3LS, GB [GB, GB], for SD only;
PATEL, Satishchandra, Punambhai, 27 Yale Court, Livingston, NJ 07039, US [US, US]
AG SMITH, Gyles, Darren, Marks & Clerk, 57-60 Lincoln's Inn Fields, London WC2A 3LS, GB
LAF English
LA English
DT Patent
PI WO 2004012770 A1 20040212
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2003-GB3278 A 20030731
PRAI GB 2002-0218003.2 20020802
ABEN The application discloses a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure

to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution comprising: (a) a pharmaceutically effective amount of a ***cyclosporin*** , in particular ***Cyclosporin*** A, (b) a ***carrier*** medium comprising a dialkyl ester of an aliphatic or ***aromatic*** ***dioic*** ***acid*** , the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or ***aromatic*** ***dioic*** ***acid*** having from 6 to 20 carbon atoms, (c) a co-***carrier*** having a hydrophilic balance (HLB) of from 3 to 6, and (d) a ***non*** - ***ionic*** ***surfactant*** having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the ***carrier*** medium are ***dibutyl*** ***sebacate*** and ***dibutyl*** ***phthalate*** . Examples of the co ***carrier*** are ***glycerol*** ***monooleate*** , ***sorbitan*** ***monooleate*** , ***glycerol*** ***monocaprylate*** , and ***sorbitan*** ***monolaurate*** .

ABFR L'invention concerne une composition pharmaceutique concue pour etre administree par voie orale, sous la forme d'une solution homogene qui, lors d'une exposition a l'eau ou aux fluides du tube digestif, presente une taille particulaire inferieure a 5 microns. Ladite solution comprend : (a) une quantite efficace pharmaceutiquement de cyclosporine, en particulier de la Cyclosporine A ; un milieu de support comprenant un ester dialkyle d'un acide dioique aliphatique ou aromatique, ledit groupe alkyle dudit ester dialkyle comportant 2 a 8 atomes de carbone et ledit acide dioique aliphatique ou aromatique comportant 6 a 20 atomes de carbone ; (c) un co-support presentant un equilibre hydrophile (HLB) compris entre 3 et 6 ; et (d) un surfactant non ionique presentant un equilibre hydrophile lipophile (HLB) superieur a 10. Selon l'invention, ledit support peut etre par exemple du sebacate de dibutyle et du phtalate de dibutyle. Selon l'invention, le co-support peut etre du ***glycerol*** ***monooleate*** , du ***sorbitan*** ***monooleate*** , du ***glycerol*** ***monocaprylate*** , et du ***sorbitan*** ***monolaurate*** .

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:119528 CAPLUS
DN 140:169649
TI Microemulsion concentrate formulations of ***cyclosporins***
IN Patel, Satishchandra Punambhai
PA USA
SO Brit. UK Pat. Appl., 15 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | GB 2391472 | A1 | 20040211 | GB 2002-18003 | 20020802 |
| | GB 2391472 | B2 | 20041208 | | |
| | CA 2494761 | AA | 20040212 | CA 2003-2494761 | 20030731 |
| | WO 2004012770 | A1 | 20040212 | WO 2003-GB3278 | 20030731 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003260706 | A1 | 20040223 | AU 2003-260706 | 20030731 |
| | EP 1572241 | A1 | 20050914 | EP 2003-766444 | 20030731 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005539002 | T2 | 20051222 | JP 2004-525534 | 20030731 |
| | US 2004102366 | A1 | 20040527 | US 2003-632969 | 20030804 |
| PRAI | GB 2002-18003 | A | 20020802 | | |
| | WO 2003-GB3278 | W | 20030731 | | |

AB A pharmaceutical compn. suitable for oral administration in the form of a homogeneous soln. which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 .mu.m, the soln. comprising: (a) a pharmaceutically effective amt. of a ***cyclosporin*** , in particular ***Cyclosporin*** A, (b) a ***carrier*** medium comprising a dialkyl ester of an aliph. or arom. ***dioic*** acid, the

alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliph. or arom. ***dioic*** acid having from 6 to 20 carbon atoms, (c) a co- ***carrier*** having a hydrophilic balance (HLB) of from 3 to 6, and (d) a ***non*** - ***ionic*** ***surfactant*** having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the ***carrier*** medium are di-Bu sebacate and di-Bu phthalate. Examples of the co- ***carrier*** are ***glycerol*** ***monooleate*** , ***sorbitan*** ***monooleate*** , ***glycerol*** ***monocaprylate*** , and ***sorbitan*** ***monolaurate*** . The compn. may take the form of a drinking soln. or a hard of soft capsule. A microemulsion for filling gelatin capsule contained ***cyclosporin*** A 100, di-Bu sebacate 220, ***glycerol*** ***monooleate*** 220, polyoxyethylene castor (Cremophore EL) 150, and .alpha.-tocopherol 5 mg.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 8 USPATFULL on STN DUPLICATE 2
AN 2003:306064 USPATFULL
TI Solid ***carriers*** for improved delivery of active ingredients in pharmaceutical compositions
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
PI US 2003215496 A1 20031120
US 6923988 B2 20050802
AI US 2003-428341 A1 20030501 (10)
RLI Continuation of Ser. No. US 2001-800593, filed on 6 Mar 2001, GRANTED, Pat. No. US 6569463 Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 81
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3364
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid ***carrier*** , the solid ***carrier*** including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid ***carrier*** , the solid ***carrier*** being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 8 USPATFULL on STN
AN 2003:257302 USPATFULL
TI Solid ***carriers*** for improved delivery of active ingredients in pharmaceutical compositions
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
PI US 2003180352 A1 20030925
AI US 2002-159601 A1 20020530 (10)
RLI Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001, PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4625
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides solid pharmaceutical compositions for

improved delivery of a wide variety of active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid ***carrier*** , the solid ***carrier*** including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides, and solubilizers. In another embodiment, the solid pharmaceutical composition includes a solid ***carrier*** , the solid ***carrier*** being formed of different combinations of active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides, and solubilizers. The compositions of the present invention can be used for improved delivery of active ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 8 USPATFULL on STN
AN 2003:112567 USPATFULL
TI Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IN Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Venkateshwaran, Srinivasan, Salt Lake City, UT, UNITED STATES
Krill, Steven L., Park City, UT, UNITED STATES
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
PI US 2003077297 A1 20030424
AI US 2002-74687 A1 20020211 (10)
RLI Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, PENDING Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192 Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001, PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 145
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 4845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 wt. % to about 80 wt. % of the active agent and the second fraction representing about 20 wt. % to about 95 wt. % of the active agent. One or more additional active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 8 USPAT2 on STN
AN 2003:92739 USPAT2
TI Solid ***carriers*** for improved delivery of hydrophobic active ingredients in pharmaceutical compositions
IN Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)
PI US 6569463 B2 20030527
AI US 2001-800593 20010306 (9)
RLI Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, now patented, Pat. No. US 6248363
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.
LREP Reed, Dianne E., Reed & Eberle LLP
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 3198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid ***carrier*** , the solid ***carrier*** including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid ***carrier*** , the solid ***carrier*** being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l2 and l3 and l4 and l5 and l7 and co-carrier
10 FILES SEARCHED...
L11 4 L2 AND L3 AND L4 AND L5 AND L7 AND CO-CARRIER

=> d bib abs 1-4

L11 ANSWER 1 OF 4 USPATFULL on STN
AN 2004:133829 USPATFULL
TI Pharmaceutical compositions
IN Patel, Satishchandra P., Livingston, NJ, UNITED STATES
PI US 2004102366 A1 20040527
AI US 2003-632969 A1 20030804 (10)
PRAI GB 2002-18003 20020802
DT Utility
FS APPLICATION
LREP Edward A. Meilman, DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 41st Floor, 1177 Avenue of the Americas, New York, NY, 10036-2714
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 433
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing:

(a) a pharmaceutically effective amount of a ***cyclosporin*** , in particular ***Cyclosporin*** A,

(b) a ***carrier*** medium which is a dialkyl ester of an aliphatic or ***aromatic*** ***dioic*** ***acid*** , the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or ***aromatic*** ***dioic*** ***acid*** having from 6 to 20 carbon atoms,

(c) a ***co*** - ***carrier*** having a hydrophilic lipophilic balance (HLB) of from 3 to 6, and

(d) a ***non*** - ***ionic*** ***surfactant*** having a hydrophilic lipophilic balance (HLB) greater than 10.

Examples of the ***carrier*** medium are ***dibutyl*** ***sebacate*** and ***dibutyl*** ***phthalate*** . Examples of the ***co*** - ***carrier*** are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2004012770 PCTFULL ED 20040219 EW 200407
TIEN ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING ***CYCLOSPORIN***
TIFR COMPOSITIONS PHARMACEUTIQUES ORALES CONTENANT DE LA CYCLOSPORINE

IN PATEL, Satishchandra, Punambhai, 27 Yale Court, Livingston, NJ 07039, US [US, US]
PA SMYTH, Gyles, Darren, 57-60 Lincoln's Inn Fields, London WC2A 3LS, GB [GB, GB], for SD only;
PATEL, Satishchandra, Punambhai, 27 Yale Court, Livingston, NJ 07039, US [US, US]
AG SMITH, Gyles, Darren, Marks & Clerk, 57-60 Lincoln's Inn Fields, London WC2A 3LS, GB
LAF English
LA English
DT Patent
PI WO 2004012770 A1 20040212
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2003-GB3278 A 20030731
PRAI GB 2002-0218003.2 20020802
ABEN The application discloses a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution comprising: (a) a pharmaceutically effective amount of a ***cyclosporin*** , in particular ***Cyclosporin*** A, (b) a ***carrier*** medium comprising a dialkyl ester of an aliphatic or ***aromatic*** ***dioic*** ***acid*** , the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or ***aromatic*** ***dioic*** ***acid*** having from 6 to 20 carbon atoms, (c) a ***co*** - ***carrier*** having a hydrophilic balance (HLB) of from 3 to 6, and (d) a ***non*** - ***ionic*** ***surfactant*** having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the ***carrier*** medium are ***dibutyl*** ***sebacate*** and ***dibutyl*** ***phthalate*** . Examples of the co ***carrier*** are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate.
ABFR L'invention concerne une composition pharmaceutique concue pour etre administree par voie orale, sous la forme d'une solution homogene qui, lors d'une exposition a l'eau ou aux fluides du tube digestif, presente une taille particulaire inferieure a 5 microns. Ladite solution comprend : (a) une quantite efficace pharmaceutiquement de cyclosporine, en particulier de la Cyclosporine A ; un milieu de support comprenant un ester dialkyle d'un acide dioique aliphatique ou aromatique, ledit groupe alkyle dudit ester dialkyle comportant 2 a 8 atomes de carbone et ledit acide dioique aliphatique ou aromatique comportant 6 a 20 atomes de carbone ; (c) un co-support presentant un equilibre hydrophile (HLB) compris entre 3 et 6 ; et (d) un surfactant non ionique presentant un equilibre hydrophile lipophile (HLB) superieur a 10. Selon l'invention, ledit support peut etre par exemple du sebacate de dibutyle et du phtalate de dibutyle. Selon l'invention, le co-support peut etre du glycerol monooleate, du sorbitan monooleate, du glycerol monocaprylate, et du sorbitan monolaurate.

L11 ANSWER 3 OF 4 IFIPAT COPYRIGHT 2006 IFI on STN
AN 10595144 IFIPAT;IFIUDB;IFICDB
TI PHARMACEUTICAL COMPOSITIONS; A HOMOGENEOUS ***CYCLOSPORIN*** SOLUTION COMPRISING A ***CARRIER*** DIALKYL ESTER OF ALIPHATIC OR ***AROMATIC*** ***DIOIC*** ***ACID*** , HYDROPHILIC LIPOPHILIC BALANCE, FORMING EMULSIONS IN STOMACH WITH GASTROINTESTINAL FLUIDS
INF Patel; Satishchandra P., Livingston, NJ, US
IN Patel Satishchandra P
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG Edward A. Meilman;DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 41st Floor, 1177 Avenue of the Americas, New York, NY, 10036-2714, US
PI US 2004102366 A1 20040527
AI US 2003-632969 20030804
PRAI GB 2002-180032 20020802
FI US 2004102366 20040527
DT Utility; Patent Application - First Publication

FS CHEMICAL
APPLICATION
CLMN 22
AB Disclosed is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing: (a) a pharmaceutically effective amount of a ***cyclosporin*** , in particular ***Cyclosporin*** A, (b) a ***carrier*** medium which is a dialkyl ester of an aliphatic or ***aromatic*** ***dioic*** ***acid*** , the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliphatic or ***aromatic*** ***dioic*** ***acid*** having from 6 to 20 carbon atoms, (c) a ***co*** - ***carrier*** having a hydrophilic lipophilic balance (HLB) of from 3 to 6, and (d) a ***non*** - ***ionic*** ***surfactant*** having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the ***carrier*** medium are ***dibutyl*** ***sebacate*** and ***dibutyl*** ***phthalate*** . Examples of the ***co*** - ***carrier*** are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate.
CLMN 22

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:119528 CAPLUS
DN 140:169649
TI Microemulsion concentrate formulations of ***cyclosporins***
IN Patel, Satishchandra Punambhai
PA USA
SO Brit. UK Pat. Appl., 15 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | GB 2391472 | A1 | 20040211 | GB 2002-18003 | 20020802 |
| | GB 2391472 | B2 | 20041208 | | |
| | CA 2494761 | AA | 20040212 | CA 2003-2494761 | 20030731 |
| | WO 2004012770 | A1 | 20040212 | WO 2003-GB3278 | 20030731 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003260706 | A1 | 20040223 | AU 2003-260706 | 20030731 |
| | EP 1572241 | A1 | 20050914 | EP 2003-766444 | 20030731 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005539002 | T2 | 20051222 | JP 2004-525534 | 20030731 |
| | US 2004102366 | A1 | 20040527 | US 2003-632969 | 20030804 |
| PRAI | GB 2002-18003 | A | 20020802 | | |
| | WO 2003-GB3278 | W | 20030731 | | |

AB A pharmaceutical compn. suitable for oral administration in the form of a homogeneous soln. which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 .mu.m, the soln. comprising: (a) a pharmaceutically effective amt. of a ***cyclosporin*** , in particular ***Cyclosporin*** A, (b) a ***carrier*** medium comprising a dialkyl ester of an aliph. or arom. ***dioic*** acid, the alkyl group of said dialkyl ester having from 2 to 8 carbon atoms, and said aliph. or arom. ***dioic*** acid having from 6 to 20 carbon atoms, (c) a ***co*** - ***carrier*** having a hydrophilic balance (HLB) of from 3 to 6, and (d) a ***non*** - ***ionic*** ***surfactant*** having a hydrophilic lipophilic balance (HLB) greater than 10. Examples of the ***carrier*** medium are di-Bu sebacate and di-Bu phthalate. Examples of the ***co*** - ***carrier*** are glycerol monooleate, sorbitan monooleate, glycerol monocaprylate, and sorbitan monolaurate. The compn. may take the form of a drinking soln. or a hard of soft capsule. A microemulsion for filling gelatin capsule contained ***cyclosporin*** A 100, di-Bu sebacate 220, glycerol monooleate 220, polyoxyethylene castor (Cremophore EL) 150, and .

***alpha*** .- ***tocopherol*** 5 mg.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 186.49 | 281.30 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -2.25 | -2.25 |

STN INTERNATIONAL LOGOFF AT 10:30:07 ON 09 MAR 2006